Medical Cannabis Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Medical Cannabis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Buds/Marijuana Flower, Cannabis Extracts), By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others), By Distribution Channel (B2B, B2C), By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others), By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Medical Cannabis Market is anticipated to experience substantial growth, expanding from USD 28.81 Billion in 2025 to USD 90.82 Billion by 2031 at a CAGR of 21.09%. This market involves the therapeutic use of the Cannabis sativa plant and its cannabinoid derivatives, such as THC and CBD, for medical conditions under professional oversight. Its expansion is driven primarily by increasing global legislative approval of medical cannabis, the rising prevalence of chronic diseases necessitating long-term pain management, and a growing geriatric population. The significant international trade volume and rapid scalability of the sector are evident, for instance, in Germany's import of nearly 57 tons of medical cannabis products in the third quarter of 2025.
Market Driver
The primary force reshaping the medical cannabis landscape is the expanding global legalization and regulatory approvals, as governments increasingly dismantle prohibitionist policies to create structured access systems. This legislative shift not only legitimizes the sector but also establishes secure avenues for physicians to prescribe cannabinoid-based medicines, thereby rapidly increasing patient enrollment in regulated systems. Examples include Australia's approval of over 113,000 Special Access Scheme applications in the first half of 2025, a 27% year-over-year increase, and Florida's medical marijuana registry exceeding 930,000 active patients by October 2025. Furthermore, the rising prevalence of chronic diseases and growing clinical evidence supporting cannabinoid efficacy for conditions like epilepsy, multiple sclerosis, and chronic pain, coupled with the urgent need for palliative care alternatives for the expanding geriatric population, further accelerate market momentum. This demand is commercially validated by the success of clinically proven cannabinoid-derived medications, such as Jazz Pharmaceuticals' Epidiolex, which generated $972.4 million in net product sales in 2024.
Market Challenge
A significant impediment to the global medical cannabis sector's scalability is the absence of harmonized regulatory frameworks across nations. Unlike the standardized international protocols governing traditional pharmaceuticals, cannabis products are subject to disparate national laws concerning Good Manufacturing Practices, labeling standards, and permissible cannabinoid concentrations. This regulatory fragmentation forces exporters to navigate unique and complex compliance regimes for each destination country, substantially increasing operational costs and delaying market entry. Consequently, companies may avoid emerging markets where compliance burdens outweigh potential revenue, leading to a concentration of supply in fewer jurisdictions rather than broad global expansion. This regulatory inconsistency also hinders growth by channeling trade into specific bilateral corridors instead of enabling a fluid global market, diverting resources from innovation and research due as manufacturers focus on administrative requirements. Canadian medical cannabis exports, for instance, reached CAD 218 million in 2024, demonstrating producers' prioritization of a limited number of aligned international markets.
Market Trends
A crucial market trend is the shift toward EU-GMP and pharmaceutical-grade product standardization, as producers increasingly prioritize stringent international quality protocols to access lucrative export markets. Leading companies are reconfiguring their operations to meet Good Manufacturing Practice (GMP) standards, particularly those required by major importers like Germany, enabling them to penetrate federally regulated jurisdictions and bypass saturated domestic markets. This strategic focus ensures product consistency and compliance, essential for integration into European and Oceanian medical supply chains, as highlighted by Aurora Cannabis' international medical cannabis net revenue more than doubling to represent 61% of its global medical cannabis revenue in Fiscal 2025 Fourth Quarter. Concurrently, the industry is witnessing an expansion of clinical trials dedicated to disease-specific therapeutic indications, signifying a transition from general wellness claims to evidence-based pharmaceutical development. Market participants are allocating substantial capital to rigorous testing to obtain regulatory approval for precise conditions, such as epilepsy or cancer-related cachexia, thereby building a competitive advantage based on intellectual property and proven efficacy. This aligns the industry with traditional biotechnology models, where value is derived from successful clinical outcomes, exemplified by Jazz Pharmaceuticals' research and development expenses reaching $809.3 million in 2024 for advancing cannabinoid-based therapies.
Key Market Players
* Canopy Growth Corporation.
* Aphria, Inc.
* Maricann Group, Inc.
* Tikun Olam - Cannabit Pharmaceuticals Ltd.
* MedReleaf Corporation
* GW Pharmaceuticals plc.
* Cannabis Sativa, Inc.
* Medical Marijuana, Inc.
* Aurora Marijuana Inc.
* Cronos Group Inc
Report Scope
In this report, the Global Medical Cannabis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Medical Cannabis Market, By Product Type
* Buds/Marijuana Flower
* Cannabis Extracts
# Medical Cannabis Market, By Active Ingredient
* Tetrahydrocannabinol (THC)
* Cannabidiol (CBD)
* Others
# Medical Cannabis Market, By Distribution Channel
* B2B
* B2C
# Medical Cannabis Market, By Application
* Chronic Pain
* Mental Disorders
* Cancer
* Epilepsy
* Others
# Medical Cannabis Market, By End User Industry
* Pharmaceutical & Biotechnology Companies
* Academic & Research Institutions
* Others
# Medical Cannabis Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Medical Cannabis Market.
Available Customizations:
Global Medical Cannabis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Medical Cannabis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
5.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
5.2.3. By Distribution Channel (B2B, B2C)
5.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
5.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. North America Medical Cannabis Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Active Ingredient
6.2.3. By Distribution Channel
6.2.4. By Application
6.2.5. By End User Industry
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Medical Cannabis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Active Ingredient
6.3.1.2.3. By Distribution Channel
6.3.1.2.4. By Application
6.3.1.2.5. By End User Industry
6.3.2. Canada Medical Cannabis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Active Ingredient
6.3.2.2.3. By Distribution Channel
6.3.2.2.4. By Application
6.3.2.2.5. By End User Industry
6.3.3. Mexico Medical Cannabis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Active Ingredient
6.3.3.2.3. By Distribution Channel
6.3.3.2.4. By Application
6.3.3.2.5. By End User Industry
7. Europe Medical Cannabis Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Active Ingredient
7.2.3. By Distribution Channel
7.2.4. By Application
7.2.5. By End User Industry
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Medical Cannabis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Active Ingredient
7.3.1.2.3. By Distribution Channel
7.3.1.2.4. By Application
7.3.1.2.5. By End User Industry
7.3.2. France Medical Cannabis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Active Ingredient
7.3.2.2.3. By Distribution Channel
7.3.2.2.4. By Application
7.3.2.2.5. By End User Industry
7.3.3. United Kingdom Medical Cannabis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Active Ingredient
7.3.3.2.3. By Distribution Channel
7.3.3.2.4. By Application
7.3.3.2.5. By End User Industry
7.3.4. Italy Medical Cannabis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Active Ingredient
7.3.4.2.3. By Distribution Channel
7.3.4.2.4. By Application
7.3.4.2.5. By End User Industry
7.3.5. Spain Medical Cannabis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Active Ingredient
7.3.5.2.3. By Distribution Channel
7.3.5.2.4. By Application
7.3.5.2.5. By End User Industry
8. Asia Pacific Medical Cannabis Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Active Ingredient
8.2.3. By Distribution Channel
8.2.4. By Application
8.2.5. By End User Industry
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Medical Cannabis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Active Ingredient
8.3.1.2.3. By Distribution Channel
8.3.1.2.4. By Application
8.3.1.2.5. By End User Industry
8.3.2. India Medical Cannabis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Active Ingredient
8.3.2.2.3. By Distribution Channel
8.3.2.2.4. By Application
8.3.2.2.5. By End User Industry
8.3.3. Japan Medical Cannabis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Active Ingredient
8.3.3.2.3. By Distribution Channel
8.3.3.2.4. By Application
8.3.3.2.5. By End User Industry
8.3.4. South Korea Medical Cannabis Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Active Ingredient
8.3.4.2.3. By Distribution Channel
8.3.4.2.4. By Application
8.3.4.2.5. By End User Industry
8.3.5. Australia Medical Cannabis Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Active Ingredient
8.3.5.2.3. By Distribution Channel
8.3.5.2.4. By Application
8.3.5.2.5. By End User Industry
9. Middle East & Africa Medical Cannabis Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Active Ingredient
9.2.3. By Distribution Channel
9.2.4. By Application
9.2.5. By End User Industry
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Medical Cannabis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Active Ingredient
9.3.1.2.3. By Distribution Channel
9.3.1.2.4. By Application
9.3.1.2.5. By End User Industry
9.3.2. UAE Medical Cannabis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Active Ingredient
9.3.2.2.3. By Distribution Channel
9.3.2.2.4. By Application
9.3.2.2.5. By End User Industry
9.3.3. South Africa Medical Cannabis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Active Ingredient
9.3.3.2.3. By Distribution Channel
9.3.3.2.4. By Application
9.3.3.2.5. By End User Industry
10. South America Medical Cannabis Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Active Ingredient
10.2.3. By Distribution Channel
10.2.4. By Application
10.2.5. By End User Industry
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Medical Cannabis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Active Ingredient
10.3.1.2.3. By Distribution Channel
10.3.1.2.4. By Application
10.3.1.2.5. By End User Industry
10.3.2. Colombia Medical Cannabis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Active Ingredient
10.3.2.2.3. By Distribution Channel
10.3.2.2.4. By Application
10.3.2.2.5. By End User Industry
10.3.3. Argentina Medical Cannabis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Active Ingredient
10.3.3.2.3. By Distribution Channel
10.3.3.2.4. By Application
10.3.3.2.5. By End User Industry
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Medical Cannabis Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Canopy Growth Corporation.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Aphria, Inc.
15.3. Maricann Group, Inc.
15.4. Tikun Olam - Cannabit Pharmaceuticals Ltd.
15.5. MedReleaf Corporation
15.6. GW Pharmaceuticals plc.
15.7. Cannabis Sativa, Inc.
15.8. Medical Marijuana, Inc.
15.9. Aurora Marijuana Inc.
15.10. Cronos Group Inc
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們